PW0787 (0.3, 1, 3, or 10 mg/kg; IP) exhibits antipsychotic-like activity by significantly inhibiting amphetamine-induced hyperlocomotor behavior in mice ^[1].

Following a single dose of 20 mg/kg orally (PO) or 10 mg/kg intravenously (IV) in rats, PW0787 demonstrates excellent plasma exposure after both PO (AUC0-inf = 13,749 ng•h/mL) and IV dosing (AUC0-inf=9030 ng•h/mL), as well as high maximum serum concentration following both PO (Cmax=3407 ng/mL) and IV administration (Cmax=6726 ng/mL). Additionally, PW0787 displays a good volume of plasma distribution (Vss=1.5 L/kg) and acceptable plasma clearance (CL=1.1 L/h/kg) after 10 mg/kg IV dosing. An excellent oral bioavailability (F) of 76% is observed ^[1].